一名71岁慢性淋巴细胞白血病患者使用嵌合抗CD20单克隆抗体利妥昔单抗后发生致命性细胞因子释放综合征。 - Suppr

Suppr

超能文献

Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.

作者信息

Lim L C, Koh L P, Tan P

出版信息

J Clin Oncol. 1999 Jun;17(6):1962-3. doi: 10.1200/jco.1999.17.6.1962.

DOI:10.1200/jco.1999.17.6.1962

PMID:10561242

Abstract

摘要

相似文献

Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.

J Clin Oncol. 1999 Jun;17(6):1962-3. doi: 10.1200/jco.1999.17.6.1962.

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

Blood. 1999 Oct 1;94(7):2217-24.

Rituximab-induced hypersensitivity pneumonitis.

Respiration. 2009;78(2):225-9. doi: 10.1159/000163069. Epub 2008 Oct 9.

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Am J Hematol. 1999 Dec;62(4):247-50. doi: 10.1002/(sici)1096-8652(199912)62:4<247::aid-ajh9>3.0.co;2-t.

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.

Blood. 2001 Sep 15;98(6):1991-2. doi: 10.1182/blood.v98.6.1991.

Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).

Ann Hematol. 1998 Jul-Aug;77(1-2):89-91. doi: 10.1007/s002770050419.

Community-based phase II trial of PCR for CLL/SLL patients.

Cancer Biother Radiopharm. 2007 Oct;22(5):713-4; author reply 715-7. doi: 10.1089/cbr.2007.0424.

[Rituximab-induced acute thrombocytopenia in a patient with chronic lymphocytic leukemia].

Rev Med Interne. 2017 May;38(5):344-346. doi: 10.1016/j.revmed.2016.08.008. Epub 2016 Sep 14.

Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab.

Ann Hematol. 2000 Jun;79(6):332-5. doi: 10.1007/s002779900141.

Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.

Int J Hematol. 2005 Nov;82(4):312-4. doi: 10.1532/IJH97.NA0504.

引用本文的文献

The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).

Int J Mol Sci. 2020 Sep 3;21(17):6412. doi: 10.3390/ijms21176412.

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.

Korean J Intern Med. 2019 Jul;34(4):885-893. doi: 10.3904/kjim.2017.036. Epub 2017 Nov 20.

Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.

J Immunol Methods. 2015 Sep;424:43-52. doi: 10.1016/j.jim.2015.04.020. Epub 2015 May 7.

Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature.

J Med Case Rep. 2013 Dec 30;7:280. doi: 10.1186/1752-1947-7-280.

Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.

Support Care Cancer. 2013 Apr;21(4):1145-52. doi: 10.1007/s00520-012-1639-9. Epub 2012 Oct 31.

Rituximab and cytokine release syndrome.

Case Rep Oncol. 2012 Jan;5(1):134-41. doi: 10.1159/000337577. Epub 2012 Mar 20.

Role of rituximab in first-line treatment of chronic lymphocytic leukemia.

Ther Clin Risk Manag. 2010 Dec 22;7:1-11. doi: 10.2147/TCRM.S5855.

A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Leukemia. 2009 May;23(5):912-8. doi: 10.1038/leu.2008.385. Epub 2009 Feb 19.

Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.

Med Oncol. 2008;25(4):437-42. doi: 10.1007/s12032-008-9062-2. Epub 2008 Apr 15.

Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.

Paediatr Drugs. 2007;9(6):371-8. doi: 10.2165/00148581-200709060-00004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.

作者信息

Lim L C, Koh L P, Tan P

出版信息

J Clin Oncol. 1999 Jun;17(6):1962-3. doi: 10.1200/jco.1999.17.6.1962.

DOI:10.1200/jco.1999.17.6.1962

PMID:10561242

Abstract

摘要

相似文献

Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.

J Clin Oncol. 1999 Jun;17(6):1962-3. doi: 10.1200/jco.1999.17.6.1962.

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

Blood. 1999 Oct 1;94(7):2217-24.

Rituximab-induced hypersensitivity pneumonitis.

Respiration. 2009;78(2):225-9. doi: 10.1159/000163069. Epub 2008 Oct 9.

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Am J Hematol. 1999 Dec;62(4):247-50. doi: 10.1002/(sici)1096-8652(199912)62:4<247::aid-ajh9>3.0.co;2-t.

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.

Blood. 2001 Sep 15;98(6):1991-2. doi: 10.1182/blood.v98.6.1991.

Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).

Ann Hematol. 1998 Jul-Aug;77(1-2):89-91. doi: 10.1007/s002770050419.

Community-based phase II trial of PCR for CLL/SLL patients.

Cancer Biother Radiopharm. 2007 Oct;22(5):713-4; author reply 715-7. doi: 10.1089/cbr.2007.0424.

[Rituximab-induced acute thrombocytopenia in a patient with chronic lymphocytic leukemia].

Rev Med Interne. 2017 May;38(5):344-346. doi: 10.1016/j.revmed.2016.08.008. Epub 2016 Sep 14.

Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab.

Ann Hematol. 2000 Jun;79(6):332-5. doi: 10.1007/s002779900141.

Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.

Int J Hematol. 2005 Nov;82(4):312-4. doi: 10.1532/IJH97.NA0504.

引用本文的文献

The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).

Int J Mol Sci. 2020 Sep 3;21(17):6412. doi: 10.3390/ijms21176412.

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.

Korean J Intern Med. 2019 Jul;34(4):885-893. doi: 10.3904/kjim.2017.036. Epub 2017 Nov 20.

Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.

J Immunol Methods. 2015 Sep;424:43-52. doi: 10.1016/j.jim.2015.04.020. Epub 2015 May 7.

Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature.

J Med Case Rep. 2013 Dec 30;7:280. doi: 10.1186/1752-1947-7-280.

Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.

Support Care Cancer. 2013 Apr;21(4):1145-52. doi: 10.1007/s00520-012-1639-9. Epub 2012 Oct 31.

Rituximab and cytokine release syndrome.

Case Rep Oncol. 2012 Jan;5(1):134-41. doi: 10.1159/000337577. Epub 2012 Mar 20.

Role of rituximab in first-line treatment of chronic lymphocytic leukemia.

Ther Clin Risk Manag. 2010 Dec 22;7:1-11. doi: 10.2147/TCRM.S5855.

A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Leukemia. 2009 May;23(5):912-8. doi: 10.1038/leu.2008.385. Epub 2009 Feb 19.

Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.

Med Oncol. 2008;25(4):437-42. doi: 10.1007/s12032-008-9062-2. Epub 2008 Apr 15.

Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.

Paediatr Drugs. 2007;9(6):371-8. doi: 10.2165/00148581-200709060-00004.